Medical treatment of advanced non-small cell lung cancer: Progress in 2014
10.11855/j.issn.0577-7402.2015.01.03
- Author:
Yong SONG
1
Author Information
1. Department of Respiratory and Critical Care Medicine, Nanjing General Hospital of Nanjing Command, Jinlin Hospital of Nanjing University
- Publication Type:Journal Article
- Keywords:
Antineoplastic protocols;
Carcinoma;
Immunotherapy;
Individualized medicine;
Molecular targeted therapy;
Non-small-cell lung
- From:
Medical Journal of Chinese People's Liberation Army
2015;40(1):10-15
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer is the most common pathological type of lung cancer. Along with the rising incidence in recent years, lung cancer has been the leading cause of death due to malignancies both in our country and worldwide. Due to simplistic therapeutic approach for lung cancer decades ago, those patients suffering from advanced lung cancer had short lifetime, and it was difficult to ensure their life quality. In recent years, many molecular targeted drugs, such as Gefitinib, Erlotinib and Crizotinib etc., have been successively applied in clinical use, and they bring about a substantial prolongation of survival life and improvement in life quality of those patients with advanced lung cancer. In 2014, there was a number of important reports concerning the diagnosis and treatment of non-small cell lung cancer in the annual meetings of either American Society of Clinical Oncology or European Society for Medical Oncology. On the basis of the relevant reports delivered in the conferences, it is our attempt to summarize the recent advances in regard to chemotherapy, molecular targeted therapy, measures to treat TKI therapy resistant cases, and immune therapy, followed by a comment regarding recent advances in the treatment of non-small cell lung cancer in 2014.
